Dichloroacetate (DCA): Insights Into Cellular Metabolism

Dichloroacetate, commonly known as DCA, is a small, structurally simple molecule that acts as a metabolic switch inside cells, pushing them to burn fuel through their mitochondria rather than through a less efficient pathway called glycolysis. It does this by blocking a family of enzymes called pyruvate dehydrogenase kinases (PDKs), which normally act as gatekeepers controlling how pyruvate, the end product of sugar breakdown, gets used. By keeping that gate open, DCA redirects pyruvate into mitochondrial oxidation, and this single shift ripples outward into cancer biology, heart disease, diabetes, rare genetic conditions, and immune function in ways researchers are still mapping out.

How DCA Flips the Metabolic Switch

To appreciate what DCA does, you need to know about one critical bottleneck in cellular energy production. After your cells break glucose down into pyruvate, that pyruvate faces a choice: it can be fermented into lactate (a quick but wasteful route) or it can enter the mitochondria and be fully oxidized for far more energy. The enzyme complex that sends pyruvate into the mitochondria is called the pyruvate dehydrogenase complex (PDC). PDC converts pyruvate into acetyl-CoA, the molecule that feeds the main energy-generating cycle inside mitochondria.

PDC, however, has its own set of off-switches: four related enzymes known as PDK1 through PDK4. When PDKs are active, they phosphorylate (effectively disable) PDC, and pyruvate gets shunted toward lactate instead. DCA was originally discovered to lower blood glucose and alter fat metabolism in diabetic rats, and researchers later identified its primary mechanism as inhibition of these PDKs.¹ By blocking PDKs, DCA keeps PDC active, so more pyruvate flows into the mitochondria for oxidation rather than being converted to lactate.

The story gets more nuanced at the level of individual PDK isoforms. Research in breast cancer, prostate cancer, and skeletal muscle cells has shown that DCA does not suppress all four PDK isoforms equally. In cancer cells, DCA predominantly reduced PDK1 levels, while in skeletal muscle cells it suppressed both PDK1 and PDK2. Part of this selectivity appears to depend on hypoxia-inducible factor-1α (HIF-1α), a protein that cancer cells frequently overexpress, and the differences between mRNA and protein changes suggest post-transcriptional mechanisms are also involved.² This means DCA’s pharmacological effects vary depending on cell type, a fact that has important implications for both its therapeutic promise and its limitations.

Cancer Cells, the Warburg Effect, and Why DCA Got So Much Attention

In 2007, a wave of media coverage turned DCA into one of the most hyped molecules in cancer research. Headlines suggested that a cheap, unpatentable chemical could kill cancer cells in the lab, and because DCA had already been used in humans for other conditions, some patients began self-medicating without waiting for clinical trials.³ The excitement was not entirely baseless, but the story the headlines told was incomplete.

The biological logic behind DCA’s anticancer interest starts with an observation made by the biochemist Otto Warburg in the 1920s. Many cancer cells prefer to ferment glucose into lactate even when oxygen is plentiful, a phenomenon now called the Warburg effect or aerobic glycolysis. This metabolic preference is not just a quirk; it helps tumors grow quickly, resist programmed cell death (apoptosis), and acidify their local environment in ways that suppress immune responses.

DCA can reverse the Warburg effect in cancer cell lines. In breast cancer cells, treatment with DCA promoted oxidative metabolism of pyruvate and reduced extracellular lactate by about half, correlating with growth inhibition and enhanced apoptosis.⁴ By forcing cancer cells to use their mitochondria, DCA also triggers the generation of reactive oxygen species (ROS). DCA depolarizes mitochondria and promotes ROS production across cell types, but cancer cells with defective mitochondrial electron transport chains are selectively more vulnerable to this stress.⁵ The elevated ROS, combined with the restored mitochondrial membrane potential changes, can tip cancer cells into apoptosis.

This selectivity is the kernel of real promise in DCA research. The idea is that normal cells, whose mitochondria work properly, can handle the metabolic shift DCA imposes, while cancer cells with dysfunctional mitochondria cannot. But translating lab results into patient outcomes has been far slower and more complicated than those early headlines suggested.

DCA in Combination With Conventional Cancer Therapies

One area where DCA research has gained traction is not as a standalone drug but as a sensitizer that makes existing cancer treatments work better. Across several cancer models, co-administration of DCA with conventional chemotherapy or radiotherapy has been tested with encouraging preclinical results.⁶

In non-small-cell lung cancer cells, combining DCA with the chemotherapy drug paclitaxel decreased autophagy (a survival mechanism tumors use to evade drug-induced death), enhanced apoptosis, and inhibited proliferation. In mice carrying lung tumor grafts, the combination significantly slowed tumor growth and extended survival compared to either drug alone.⁷ Similarly, in breast cancer cells with wild-type P53, combining DCA with doxorubicin significantly reduced cell viability after just 24 hours, with the strongest inhibition seen in MCF7 cells.⁸

The rationale for these combinations makes metabolic sense. By shifting cancer cells away from glycolysis, DCA may strip them of the metabolic flexibility they rely on to survive chemotherapy or radiation. Tumors that depend on autophagy to recycle damaged components during treatment stress find that escape route partially blocked when DCA is added. The challenge remains getting these findings out of the lab and into well-powered clinical trials in humans.

Reshaping the Tumor Immune Environment

One of the less obvious consequences of the Warburg effect is that tumors dump lactic acid into their surroundings. This acidic microenvironment suppresses the immune cells that would otherwise attack the tumor, creating a kind of metabolic shield. DCA’s ability to cut lactate production opens an interesting angle for immunotherapy.

In tumor models, DCA decreased lactic acid concentrations by shifting glucose metabolism in tumor cells. The result was increased T cell proliferation and cytokine production, along with rescue of T cells from lactic acid-induced apoptosis.⁹ Separately, DCA was shown to suppress lactic acid-driven activation of immunosuppressive pathways in macrophages, restore CD8+ T cell proliferation that macrophages had been inhibiting, and increase the numbers of interferon-gamma-producing killer T cells and natural killer cells in the spleens of tumor-bearing mice.¹⁰

There is a complication, though. DCA does not just affect tumor cells; it also alters the metabolism of immune cells themselves. In human lymphocytes, DCA at therapeutic concentrations inhibited aerobic glycolysis and markedly increased the expression of FOXP3 and production of IL-10, both markers of regulatory T cells. Regulatory T cells suppress immune activity, which could counteract the very anti-tumor immune response DCA is meant to unleash.¹¹ This tension between improving the immune environment inside the tumor and potentially dampening systemic immune surveillance is one of the unresolved puzzles in DCA research.

Lactic Acidosis and Mitochondrial Disease

Before DCA became associated with cancer in the public imagination, its longest-running clinical use was in treating lactic acidosis, particularly in children with inherited mitochondrial diseases. Conditions like pyruvate dehydrogenase (PDH) deficiency cause dangerous accumulations of lactate in the blood because the enzyme needed to burn pyruvate in the mitochondria does not work properly. DCA, by inhibiting the kinases that further shut down PDC, can partially compensate and keep blood lactate in check.

Long-term data from children with congenital lactic acidosis showed that chronic oral DCA maintained normal blood lactate levels, even in PDH-deficient children eating essentially unrestricted diets (rather than the strict ketogenic diets typically required). Blood counts, kidney function, and liver markers remained stable over extended treatment.¹² This finding is meaningful for families managing these rare diseases, where dietary restrictions are a daily burden.

The picture changes with age, however. While young children in clinical trials generally tolerated DCA well, a controlled trial in older adolescents and adults with the mitochondrial disease MELAS had to be stopped early because of a high rate of new or worsening peripheral neuropathy that appeared within weeks or months of starting DCA.¹³ This age-dependent difference in toxicity is a recurring theme in DCA pharmacology and connects directly to how the drug is processed in the body.

Why DCA Gets Harder to Clear With Repeated Doses

DCA is metabolized by an enzyme called glutathione transferase zeta 1 (GSTZ1). In an unusual twist, DCA irreversibly inactivates the very enzyme responsible for breaking it down. This means repeated dosing leads to progressively slower drug clearance, causing DCA to accumulate in the body over time.¹⁴ Pharmacokinetic modeling in rats estimated that DCA inactivates GSTZ1 over 100 times faster than the enzyme naturally degrades, which explains why plasma DCA levels climb with chronic use.

This autoinhibition is more pronounced in adults than in children. In rat models, GSTZ1 activity in the cell’s main fluid compartment was inactivated more rapidly in adult animals than in juveniles after a single DCA dose, and within the mitochondria specifically, GSTZ1 was knocked out even faster than in the surrounding cell fluid.¹⁵ The difference appears to involve intracellular chloride concentrations: mitochondria have much lower chloride levels than the surrounding cytoplasm, and chloride protects GSTZ1 from DCA-induced inactivation. In human liver tissue, the degree of protection from chloride also depends on which genetic variant of GSTZ1 a person carries. People with the EGT haplotype retained substantially more enzyme activity after DCA exposure than those with the KRT haplotype.¹⁶

This pharmacogenomic wrinkle means that the same dose of DCA can behave very differently in two people. Someone with a GSTZ1 variant that is rapidly inactivated by DCA will accumulate the drug faster and face higher risk of toxicity, while someone with a more resistant variant may clear it more efficiently. If DCA ever progresses to routine clinical use, genotyping for GSTZ1 haplotype could become an important step in dose selection.

Peripheral Neuropathy and the Limits of Chronic Use

The most significant barrier to long-term DCA therapy is its tendency to damage peripheral nerves. In rats, both juvenile and adult animals treated with DCA at doses similar to clinical use developed nerve conduction slowing, with adult rats affected more severely. The damage involved reduced caliber of myelinated nerve fibers and accumulation of oxidative stress markers in nerve tissue, even without overt axonal breakdown visible under the microscope.¹⁷

In vitro work has illuminated a possible mechanism. DCA caused a dose- and exposure-dependent decrease in myelin-related proteins in nerve cell cultures, and partial recovery occurred after a 10-day washout period, suggesting the damage is at least partly reversible.¹⁸ Clinical observations align with this: in a pediatric case report, a child with complex I deficiency developed reversible peripheral polyneuropathy on DCA despite receiving thiamine supplementation, though brain imaging remained normal, suggesting DCA’s neurotoxicity targets peripheral nerves specifically.¹⁹

The reversibility is reassuring but not absolute. Mild neuropathy in children on long-term DCA has sometimes required dose reduction or temporary discontinuation, though symptomatic worsening has been uncommon in younger patients.¹² In adults, the risk is higher and onset is faster, which tracks with the age-dependent GSTZ1 inactivation kinetics described above. Higher drug accumulation in adults may expose nerves to DCA for longer periods at higher concentrations, amplifying the oxidative stress that seems to underlie the neuropathy.

Heart Protection During Ischemia

When blood flow to the heart is interrupted and then restored (ischemia-reperfusion), the heart shifts its metabolism in harmful ways. The damaged tissue relies more on fatty acid oxidation and glycolysis, producing less ATP and generating toxic byproducts. DCA’s ability to boost glucose oxidation has been tested as a way to improve recovery after cardiac ischemia.

In isolated rat hearts, adding DCA to the reperfusion fluid increased glucose oxidation rates roughly four-fold and improved mechanical recovery to about 73% of pre-ischemic function.²⁰ More recent work has explored the downstream mechanisms and found that DCA reduced infarct size, lowered arrhythmia scores, improved heart contractile function, and reduced markers of cardiac damage. These protective effects appeared to involve regulation of autophagy and improved glucose uptake through increased expression of glucose transporters.²¹

DCA has also shown effects in pulmonary arterial hypertension (PAH), a condition where the blood vessels in the lungs narrow due to abnormal proliferation of smooth muscle cells. In animal models, DCA depolarized mitochondria in these cells, triggered a ten-fold increase in apoptosis within the vessel walls, and decreased proliferation.²² In a genetic mouse model of PAH, DCA partially reversed established disease by the same mechanism of reducing proliferation and increasing apoptosis in muscularized pulmonary arteries.²³

Blood Sugar and Diabetes

DCA’s original discovery in the context of diabetic rats has come full circle with more recent mechanistic work on type 2 diabetes. In normal rats, a single DCA dose lowered plasma pyruvate and blood glucose, but only in the fasting state. In diabetic mice, a single dose lowered blood glucose and a three-week course decreased fructosamine, a longer-term marker of blood sugar control. The mechanism appears to involve two things at once: DCA restricts the supply of gluconeogenic substrates (pyruvate and lactate) from muscle to liver, and it directly suppresses the liver’s production of new glucose from those substrates.²⁴

This dual action on gluconeogenesis is mechanistically distinct from how most diabetes drugs work. Rather than increasing insulin production or sensitivity, DCA cuts off the raw materials the liver needs to manufacture glucose, effectively attacking the problem from the supply side. Whether this translates into a viable diabetes therapy remains to be seen, given the neuropathy concerns with chronic dosing, but the metabolic logic is sound and DCA continues to serve as a research tool for understanding how gluconeogenic flux contributes to hyperglycemia.

Epigenetic Ripple Effects

An emerging area of DCA research concerns its effects on gene regulation through epigenetic mechanisms. When DCA promotes the conversion of pyruvate into acetyl-CoA, it does not just feed the mitochondrial energy cycle; acetyl-CoA is also the raw material for histone acetylation, a chemical modification that opens up DNA for gene expression. Under low-oxygen conditions (hypoxia), which are common inside tumors, cells ramp up PDK activity and produce less acetyl-CoA, leading to a loss of histone acetylation and a shift toward a more undifferentiated, aggressive cell state.

DCA treatment was shown to restore histone acetylation under hypoxia in a dose-dependent manner, with particularly strong effects on a specific mark (H3K27 acetylation) associated with active gene expression. Isotope tracing confirmed that DCA increased the fraction of acetyl-CoA derived from pyruvate entering the mitochondrial cycle, verifying that PDH activity had been partially rescued.²⁵ In practical terms, this means DCA may not only affect energy metabolism but also influence which genes tumors can access and express, potentially pushing cancer cells toward a more differentiated, less aggressive phenotype.

Targeted Delivery and Next-Generation DCA Compounds

One of DCA’s practical problems is that it is a small, water-soluble molecule with limited ability to concentrate where it is needed. Researchers have been engineering delivery systems that package DCA for targeted arrival at mitochondria, where its target enzyme complex sits.

A compound called Mito-DCA attached multiple DCA molecules to a scaffold carrying a lipophilic cation that naturally accumulates in mitochondria. The result was roughly a thousand-fold increase in potency compared to free DCA, with specificity for cancer cells. Mito-DCA caused tumor cells with dysfunctional mitochondria to switch from glycolysis to oxidation and undergo apoptosis, while showing no significant metabolic effects on normal cells.²⁶ A polymer micelle system (OPDEA-PDCA) targeting mitochondria in osteosarcoma cells took a different approach, inducing mitochondrial oxidative stress that triggered pyroptosis, a form of inflammatory cell death that alerts the immune system to the presence of the tumor.²⁷

These delivery strategies address two problems at once: they reduce the systemic exposure that causes neuropathy and liver effects, and they increase the concentration of DCA where it actually needs to act. If any of these platforms reach clinical testing, they could change the calculus on DCA toxicity entirely.

Why Some Tumors Respond and Others Don’t

Not all cancer cells react the same way to DCA, and understanding who might benefit requires better biomarkers. NMR-based metabolic profiling of prostate cancer cells illustrated this starkly. When treated with DCA, highly metastatic prostate cancer cells showed significant reductions in lactate ratios relative to other metabolites, while poorly metastatic cells from the same lineage showed no meaningful metabolic response. The difference appeared related to the absence of a particular lactate dehydrogenase subunit in the aggressive cells.²⁸

This finding is a useful reminder that metabolic therapies are not one-size-fits-all. A tumor’s specific metabolic wiring, including which enzyme subunits it expresses and which PDK isoforms dominate, shapes whether DCA will have a meaningful effect. The development of metabolic profiling methods that can be applied to a patient’s tumor tissue could eventually help clinicians decide who is most likely to benefit from DCA-based regimens, rather than treating all tumors as metabolically identical.